04:50 PM EDT, 07/02/2024 (MT Newswires) -- Tyra Biosciences ( TYRA ) said Tuesday it plans to develop TYRA-300 for the potential treatment of hypochondroplasia following encouraging results in the preclinical proof-of-concept study.

The company expects to file an investigational new drug application with the US Food and Drug Administration in H2 and plans to start a phase two study in pediatric achondroplasia.